PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
about
Potential use of rapamycin in HIV infectionRapamycin and rapalogs for tuberous sclerosis complexMnk kinase pathway: Cellular functions and biological outcomesMYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsRecent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agentsS6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancerActivating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.mTOR and cancer: many loops in one pathway.Chemotactic activation of Dictyostelium AGC-family kinases AKT and PKBR1 requires separate but coordinated functions of PDK1 and TORC2Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitorsRecent advances in the discovery of small molecule mTOR inhibitors.Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity.Phosphatidylinositol 3-kinase: the oncoprotein.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Tangeretin and its metabolite 4'-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6KFrontier of epilepsy research - mTOR signaling pathway.A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens.AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsRSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs availableEstablishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Current and future directions in mammalian target of rapamycin inhibitors development.The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs.Targeting Mnks for cancer therapy.Caspase control: protagonists of cancer cell apoptosis.PDK1 inhibitorsPDK1 disruptors and modulators: a patent review.Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerRecent advances in targeting mTOR signaling pathway using small molecule inhibitors.Expression and clinical significance of Semaphorin4D in non-small cell lung cancer and its impact on malignant behaviors of A549 lung cancer cells.Astrocyte elevated gene-1 mediates glycolysis and tumorigenesis in colorectal carcinoma cells via AMPK signaling.The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.Safety profile and treatment response of everolimus in different solid tumors: an observational study.Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts.Synthesis and antitumor activity of inositol phosphotriester analogues.Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
P2860
Q24606795-DA0397F0-2BA7-43AD-957E-9073C6318D6DQ26471128-1C019338-9A65-4F06-9090-87620B595AB2Q26865459-C0A2D430-B44F-4AEC-B713-FA8B2BD0DDE6Q27350187-7329B3E9-B645-4747-B33A-2DD7D4B88714Q28067417-52C2677D-E930-480E-8556-CC7F65FD6AA4Q28477972-A665DD89-46E1-46BF-9CEF-96D8A8931990Q30437618-794A7713-EE09-4F14-B2AB-A20F47053F29Q33348248-23ECBCBE-8FC3-46BF-9745-D207A372DAA8Q33701947-7756FDFF-FADD-46C7-A42C-EB7A254ECE50Q33702325-03B4C27E-DAE2-45C3-B8BF-659C53B7A315Q33852446-31450FA6-17FA-48B7-A867-09809DDEB2ECQ33977840-EF2F3094-A4EA-498C-94F3-1FFAF6DCD362Q34203861-035A3FCB-3E00-49AE-8999-3E3FDD6AB973Q34260622-D6701B76-1054-41BE-BE7F-8AEA876B5F98Q34307356-27F9CB60-0D48-4037-828A-C101B679B011Q34442835-D150053F-6CC2-4506-A704-E09E74AED03EQ34837773-6CAC5C52-6454-4A9D-94C2-03B53ADBEE39Q35014198-F095254E-CB72-449C-BE5B-D7FC468C8D2CQ35186717-619AE86D-0DDE-4557-B277-8EF23B6BD79BQ35886886-7A50EC31-99CB-4BD4-9A6D-EE44429F482EQ36273796-4E9E084A-8682-4C7B-9549-90FC882CBC08Q36891050-9CD54DE0-5F5A-4276-BB9C-7D1D6123FBC4Q36896122-7A40FEFB-3E24-45C1-85C2-020049F1E06FQ37144315-303DAD92-25E5-49FD-B10F-CDC09098D953Q37588340-CC7D25E1-9B7C-4836-A864-431C396004D6Q37836904-A1979037-1974-42E8-B839-E6190D552A21Q37880903-A15C6CD2-6F06-4DA6-9E75-66269409F28DQ37990881-8BDAC8C9-FF72-4F99-91A7-55F0014F47C8Q38052382-5DCA4058-4466-4C6A-8516-48021091B0BAQ38162915-5475A73E-2DB0-4B84-B0A0-F8460002FEB0Q38356458-BD061CD5-B728-4ED6-8AAB-D151DC1A11E9Q38751569-E4FFE826-FAF4-4B60-989E-A664AB62A643Q38955246-E9CB08A6-B425-4580-8BF3-1DB5998A54BFQ38964772-41892AC4-54D6-47EB-AB42-CED5D3B2AC2CQ38994833-1B45AFBB-30FC-4F52-8EC1-487208EE3AE2Q39035073-ABC184D7-82F3-4C5C-B8B4-ABD9514C62EEQ39141798-50D4BCFA-E35A-422D-B7FA-09DEC83F861BQ39346141-3F3DC9B3-F178-41DF-A71B-B82C2862DC10Q39370488-38272B21-A47A-491B-98B2-01AFA947B033Q39380262-E3B875ED-718A-4FB9-842B-5227695D51BB
P2860
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@ast
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@en
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@nl
type
label
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@ast
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@en
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@nl
prefLabel
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@ast
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@en
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@nl
P2093
P1476
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
@en
P2093
Carlos García-Echeverría
Christine Fritsch
Saskia Brachmann
Saveur-Michel Maira
P304
P356
10.1016/J.CEB.2008.12.011
P577
2009-02-07T00:00:00Z